Management of Low-Stage Testicular Seminoma

Urologic Clinics of North America

Volumn 34, Issue 2, 2007, Pages 127-136

  Neill, Mischel ^a   Warde, Padraig ^a   Fleshner, Neil ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MEDICAL SPECIALIST; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; ORCHIECTOMY; PATIENT COMPLIANCE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; REVIEW; SEMINOMA; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME;

CLINICAL TRIALS; HUMANS; INCIDENCE; MALE; NEOPLASM STAGING; RISK FACTORS; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34247891646     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.02.009     Document Type: Review

References (71)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
2. Chung P., and Warde P. Surveillance in stage I testicular seminoma. Urol Oncol 24 1 (2006) 75-79
3. McGlynn K.A., Devesa S.S., Graubard B.I., et al. Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol 23 24 (2005) 5757-5761
4. McGlynn K.A., Devesa S.S., Sigurdson A.J., et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97 1 (2003) 63-70
5. Ulbright T.M., et al. Testicular and paratesticular tumors. In: Mills S.E., Greenson J.K., Oberman H.A., et al. (Eds). Sternberg's diagnostic surgical pathology. 4th edition (2004), Lippincott Williams & Wilkins, Philadelphia 2168
6. Hofer M.D., Browne T.J., He L., et al. Identification of two molecular groups of seminomas by using expression and tissue microarrays. Clin Cancer Res 11 16 (2005) 5722-5729
7. Cheville J.C. Classification and pathology of testicular germ cell and sex cord-stromal tumors. Urol Clin North Am 26 3 (1999) 595-609
8. Eble J.N. Spermatocytic seminoma. Hum Pathol 25 10 (1994) 1035-1042
9. Steiner H., Gozzi C., Verdorfer I., et al. Metastatic spermatocytic seminoma-an extremely rare disease. Eur Urol 49 1 (2006) 183-186 [Epub 2005 Nov 8]
10. Looijenga L.H., Hersmus R., Gillis A.J., et al. Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res 66 1 (2006) 290-302
11. Verdorfer I., Rogatsch H., Tzankov A., et al. Molecular cytogenetic analysis of human spermatocytic seminomas. J Pathol 204 3 (2004) 277-281
12. Clinical Oncology Information Network (CION) Guidelines. Guidelines on the management of adult testicular cancer. J Clin Oncol 12 5 (2000) S173-S210
13. Weir H.K., Marrett L.D., and Moravan V. Trends in the incidence of testicular germ cell cancer in Ontario by histologic subgroup, 1964-1996. CMAJ 160 (1999) 201-205
14. Bosl G., Goldman A., Lange P., et al. Impact of the delay in diagnosis on clinical stage of testicular cancer. Lancet 2 (1981) 970-973
15. Moul J., Paulson D., Dodge R., et al. Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol 143 (1990) 520-523
16. Carver B.S., and Sheinfeld J. Germ cell tumors of the testis. Ann Surg Oncol 12 (2005) 871-880
17. Capelouto C., Clark P., Ransil B., et al. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary?. J Urol 153 (1995) 1397-1401
18. Oliver R.T., Ong J., Blandy J.P., et al. Testis conservation in germ cell cancer justified by improved primary chemotherapy response and reduced delay, 1978-1994. Br J Urol 78 (1996) 119-124
19. Delaney R.J., Sayers C.D., Walker M.A., et al. The continued value of central histopathological review of testicular tumors. Histopathology 47 (2005) 166-169
20. von der Maase H., Specht L., Jacobsen G.K., et al. Surveillance following orchidectomy for stage 1 seminoma of the testis. Eur J Cancer 29A (1993) 1931-1934
21. Hilton S., Herr H., Teitcher J., et al. CT detection of retroperitoneal lymph node metastases in patients with clinical stage 1 testicular non-seminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 169 (1997) 521-525
22. Anzai Y., Piccoli C.W., Outwater E.K., et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 228 (2003) 777-788
23. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (2003) 2491-2499
24. Wilson C.B., Young H.E., Ott R.J., et al. Imaging metastatic germ cell tumors with 18FDG positron emission tomography: prospects of detection and management. Eur J Nucl Med 22 (1995) 508-513
25. De Santis M., and Pont J. The role of positron emission tomography in germ cell cancer. World J Urol 22 (2004) 41-46
26. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15 (1997) 594-603
27. Weissbach L., Bussar-Maatz R., Lohrs U., et al. Prognostic factors in seminomas with respect to HCG: results of a prospective multicenter study. Eur Urol 36 (1999) 601-608
28. Bruns F., Raub M., Schaefer U., et al. No predictive value of β-hCG in patients with stage 1 seminoma-results of a long-term follow-up study after adjuvant radiotherapy. Anticancer Res 25 (2005) 1543-1546
29. Ackers C., and Rustin G.J.S. Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage 1 germ cell tumors. Br J Cancer 94 (2006) 1231-1232
30. Dosmann M.A., and Zagars G.K. Post-orchiectomy radiotherapy for stages I and II testicular seminoma. Int J Radiat Oncol Biol Phys 26 (1993) 381-390
31. Fossa S.D., Aass N., and Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 16 (1989) 383-388
32. Giaccheti S, Raoul Y, Wibault P, et al. Treatment of stage I testis seminoma by radiotherapy: long-term results-a 30 year experience. Int J Radiat Oncol Biol Phys 1993;27:3-9.
33. Warde P., Gospodarowicz M.K., Panzarella T., et al. Stage I testicular seminoma: results of adjuvant radiation and surveillance. J Clin Oncol 13 (1995) 2255-2262
34. Steele G.S., Richie J.P., Stewart A.K., et al. The national cancer database report on patterns of care for testicular carcinoma, 1986-1996. Cancer 86 (1999) 2171-2183
35. Horwich A., Alsanjari N., Ahern R., et al. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65 (1992) 775-778
36. Ramakrishnan S., Champion A.E., Doreen M.S., et al. Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine post-operative radiotherapy?. Clin Oncol (R Coll Radiol) 4 (1992) 284-286
37. Aparicio J., Muro G., Maroto P., et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14 (2003) 867-872
38. Choo R., Thomas G., Woo T., et al. Long term outcome of postorchidectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 61 (2005) 736-740
39. Michael H., Lucia J., Foster R.S., et al. The pathology of late recurrences of testicular germ cell tumors. Am J Surg Pathol 24 (2000) 257-273
40. Warde P., Gospodarowicz M., Panzarella T., et al. Issues in the management of stage I testicular seminoma. Int J Radiat Oncol Biol Phys 39 (1997) 156-159
41. Sharda N.N., Kinsella T.J., and Ritter M.A. Adjuvant radiation vs. observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. J Clin Oncol 14 (1996) 2993-2999
42. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 1999;17:1146-54.
43. Senturia Y.D., Peckham C.S., and Peckham M.J. Children fathered by men treated for testicular cancer. Lancet 2 (1985) 766-769
44. Zagars G.K., Ballo M.T., Lee A.K., et al. Mortality after cure of testicular seminoma. J Clin Oncol 22 (2004) 640-647
45. Huddart R.A., Norman A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21 (2003) 1513-1523
46. Caffo O., Amichetti M., Tomio L., et al. Quality of life after radiotherapy for early-stage testicular seminoma. Radiother Oncol 59 (2001) 13-20
47. Tinkler S.D., Howard G.C., and Kerr G.R. Sexual morbidity following radiotherapy for germ cell tumors of the testis. Radiother Oncol 25 (1992) 207-212
48. Fossa S.D., Chen J., Schonfeld S.J., et al. Risk of contralateral testicular cancer: a population based study of 29,515 US men. J Natl Cancer Inst 97 (2005) 1056-1066
49. Travis L.B., Fossa S.D., Schonfeld S.J., et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97 (2005) 1354-1365
50. Hao D., Seidel J., Brant R., et al. Compliance of clinical stage I non-seminomatous germ cell tumor patients with surveillance. J Urol 160 (1998) 768-771
51. Alomary I., Samant R., and Gallant V. Treatment of stage I seminoma: a 15 year review. Urol Oncol 24 (2006) 180-183
52. Warde P., Specht L., Horwich A., et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20 (2002) 4448-4452
53. Jones W.G., Fossa S.D., Mead G.M., et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23 6 (2005) 1200-1208
54. Schmoll H.J., Souchon R., Krege S., et al. European consensus on diagnosis and treatment of germ cell cancer, a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15 (2004) 1377-1399
55. Niazi T.M., Souhami L., Sultanem K., et al. Long-term results of para-aortic irradiation for patients with stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 61 3 (2005) 741-744
56. Classen J., Schmidberger H., Meisner C., et al. German Testicular Cancer Study Group (GTCSG) Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 90 12 (2004) 2305-2311
57. Niewald M., Waziri A., Walter K., et al. Low dose radiotherapy for stage I seminoma: early results. Radiother Oncol 37 (1995) 164-166
58. Kiricuta IC, Sauer J, Bohndorf W. Omission of pelvic irradiation on stage I testicular seminoma: a study of postorchiectomy para-aortic radiotherapy. Int J Radiat Oncol Biol Phys 1009;35:293-298.
59. Logue J.P., Harris M.A., Livsey J.E., et al. Short course para-aortic radiation for stage I seminoma of the testis. Int J Radiol Oncol Biol Phys 57 (2003) 1304-1309
60. Oliver T. One-dose carboplatin in seminoma. [correspondence]. Lancet 366 (2005) 1526
61. Power R.E., Kennedy L., Crown J., et al. Pelvic recurrence in stage I seminoma: a new phenomenon that questions modern protocols for radiotherapy and follow-up. Int J Urol l2 (2005) 378-382
62. Oliver R.T., Mason M.D., Mead G.M., et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet 366 (2005) 293-300
63. Dieckmann K.P., Bruggeboes B., Pichlmeier U., et al. Adjuvant treatment of clinical stage I seminoma: as a single course of carboplatin sufficient?. Urology 55 (2000) 102-106
64. Steiner H., Holtl I., and Witenberger W. Long term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single center study. Urology 60 (2002) 324-328
65. Reiter W.J., Brodowicz T., Alavi S., et al. Twelve year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19 (2001) 101-104
66. Zagars G.K., and Pollack A. Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 51 (2001) 634-639
67. Chung P.W., Warde P.R., Panzerella T., et al. Appropriate radiation volume for stage IIA/B testicular seminoma. Int J Radiat Oncol Biol Phys 56 (2003) 746-748
68. Loehrer P., Birch R., Williams S., et al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 5 (1987) 1212-1220
69. Claasen J., Schmidberger H., Meisner C., et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21 (2003) 1101-1106
70. Chung P.W., Gospodarowicz M.K., Panzarella T., et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 45 (2004) 754-759
71. Patterson H., Norman A.R., Mitra S.S., et al. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: a comparison with radiotherapy treatment alone. Radiother Oncol 59 (2001) 5-11